Teva Pharmaceutical Industries Limited (LON:0LER)
London
· Delayed Price · Currency is GBP · Price in USD 31.43
-1.09 (-3.35%)
At close: Mar 5, 2026
LON:0LER Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 17,258 | 16,544 | 15,846 | 14,925 | 15,878 | Upgrade
|
| Revenue Growth (YoY) | 4.32% | 4.41% | 6.17% | -6.00% | -4.69% | Upgrade
|
| Cost of Revenue | 8,320 | 8,481 | 8,200 | 7,952 | 8,284 | Upgrade
|
| Gross Profit | 8,938 | 8,063 | 7,646 | 6,973 | 7,594 | Upgrade
|
| Selling, General & Admin | 3,973 | 3,702 | 3,498 | 3,445 | 3,528 | Upgrade
|
| Research & Development | 1,013 | 998 | 953 | 838 | 967 | Upgrade
|
| Other Operating Expenses | - | -10 | 10 | 28 | 20 | Upgrade
|
| Operating Expenses | 4,986 | 4,690 | 4,461 | 4,311 | 4,515 | Upgrade
|
| Operating Income | 3,952 | 3,373 | 3,185 | 2,662 | 3,079 | Upgrade
|
| Interest Expense | -916 | -1,002 | -1,029 | -930 | -891 | Upgrade
|
| Interest & Investment Income | 92 | 86 | 68 | 10 | - | Upgrade
|
| Earnings From Equity Investments | 15 | 1 | 2 | 21 | 9 | Upgrade
|
| Currency Exchange Gain (Loss) | -41 | -17 | -30 | 16 | -7 | Upgrade
|
| Other Non Operating Income (Expenses) | -71 | -48 | -66 | -62 | -69 | Upgrade
|
| EBT Excluding Unusual Items | 3,031 | 2,393 | 2,130 | 1,717 | 2,121 | Upgrade
|
| Merger & Restructuring Charges | -225 | -74 | -111 | -146 | -133 | Upgrade
|
| Impairment of Goodwill | - | -1,280 | -700 | -2,045 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -90 | Upgrade
|
| Gain (Loss) on Sale of Assets | -20 | 17 | 28 | 64 | 58 | Upgrade
|
| Asset Writedown | -1,028 | -1,275 | -378 | -402 | -584 | Upgrade
|
| Legal Settlements | -467 | -761 | -1,043 | -2,069 | -698 | Upgrade
|
| Other Unusual Items | -54 | -303 | -548 | -261 | -7 | Upgrade
|
| Pretax Income | 1,237 | -1,283 | -622 | -3,142 | 667 | Upgrade
|
| Income Tax Expense | -180 | 676 | -7 | -643 | 211 | Upgrade
|
| Earnings From Continuing Operations | 1,417 | -1,959 | -615 | -2,499 | 456 | Upgrade
|
| Minority Interest in Earnings | -7 | 320 | 56 | 53 | -39 | Upgrade
|
| Net Income | 1,410 | -1,639 | -559 | -2,446 | 417 | Upgrade
|
| Net Income to Common | 1,410 | -1,639 | -559 | -2,446 | 417 | Upgrade
|
| Shares Outstanding (Basic) | 1,145 | 1,131 | 1,119 | 1,110 | 1,102 | Upgrade
|
| Shares Outstanding (Diluted) | 1,163 | 1,131 | 1,119 | 1,110 | 1,107 | Upgrade
|
| Shares Change (YoY) | 2.83% | 1.07% | 0.81% | 0.27% | 1.10% | Upgrade
|
| EPS (Basic) | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 | Upgrade
|
| EPS (Diluted) | 1.21 | -1.45 | -0.50 | -2.20 | 0.38 | Upgrade
|
| Free Cash Flow | 1,148 | 749 | 842 | 1,042 | 236 | Upgrade
|
| Free Cash Flow Per Share | 0.99 | 0.66 | 0.75 | 0.94 | 0.21 | Upgrade
|
| Gross Margin | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% | Upgrade
|
| Operating Margin | 22.90% | 20.39% | 20.10% | 17.84% | 19.39% | Upgrade
|
| Profit Margin | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% | Upgrade
|
| Free Cash Flow Margin | 6.65% | 4.53% | 5.31% | 6.98% | 1.49% | Upgrade
|
| EBITDA | 4,954 | 4,432 | 4,338 | 3,970 | 4,409 | Upgrade
|
| EBITDA Margin | 28.71% | 26.79% | 27.38% | 26.60% | 27.77% | Upgrade
|
| D&A For EBITDA | 1,002 | 1,059 | 1,153 | 1,308 | 1,330 | Upgrade
|
| EBIT | 3,952 | 3,373 | 3,185 | 2,662 | 3,079 | Upgrade
|
| EBIT Margin | 22.90% | 20.39% | 20.10% | 17.84% | 19.39% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 31.63% | Upgrade
|
| Advertising Expenses | - | - | - | - | 246 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.